T1-T4N0期喉癌的根治性放疗。

Definitive irradiation of T1-T4N0 larynx cancer.

作者信息

Chacko D C, Hendrickson F R, Fisher A

出版信息

Cancer. 1983 Mar 15;51(6):994-1000. doi: 10.1002/1097-0142(19830315)51:6<994::aid-cncr2820510605>3.0.co;2-f.

DOI:10.1002/1097-0142(19830315)51:6<994::aid-cncr2820510605>3.0.co;2-f

Abstract

The use of definitive irradiation in T1-T4N0 larynx cancer was reviewed in 236 patients at Rush-Presbyterian-St. Luke's Medical Center in Chicago. Recurrence-free survival for all stages was 86% at five years. Ultimate recurrence-free survival, including successful surgical salvage, was 91% at five years. The data described herein and the literature reviewed support the recommendation for definitive radiation therapy for T1 and T2N0 larynx cancer of any site. T3 lesions may also be reasonably treated with radiation therapy initially, reserving surgery for salvage. However, more data are needed to accurately identify the T3 larynx cancer patients most suited for radiation therapy.

摘要

芝加哥拉什长老会圣卢克医疗中心对236例T1-T4N0期喉癌患者采用根治性放疗的情况进行了回顾。所有分期的无复发生存率在5年时为86%。包括成功手术挽救在内的最终无复发生存率在5年时为91%。本文所述数据及所回顾的文献支持对任何部位的T1和T2N0期喉癌采用根治性放射治疗的建议。T3期病变最初也可合理地采用放射治疗，保留手术用于挽救。然而，需要更多数据来准确识别最适合放射治疗的T3期喉癌患者。